Effect of Abhaya Ghana Vati along with Pathya Aaahara Vihara (Diet and Lifestyle Regime) on Patients of Diabesity – A Single Arm Clinical Trial

Jump To References Section

Authors

  • Aishwarya Ashish Joglekar
     Department of Samhita Siddhant, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi - 110076, Delhi, India ,IN
  • Mahesh Vyas
     Department of Samhita Siddhant, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi - 110076, Delhi, India ,IN
  • Meera K. Bhojani
     Department of Sharira Kriya, All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi - 110076, Delhi, India ,IN
  • Anil Kumar
     All India Institute of Ayurveda, Gautampuri, Sarita Vihar, New Delhi - 110076, Delhi, India ,IN

DOI:

https://doi.org/10.18311/jnr/2023/32931

Keywords:

Selected:Selected:Abhaya Ghana Vati, Diabesity, Diabetes, Obesity, Pathya Aahara Vihaara, Sthula Pramehi, Sthoulya, Prameha

Abstract

Introduction: Ayurveda beautifully amalgamates herbal drugs and lifestyle modifications in the management of various diseases and lifestyle disorders. Diabesity is one condition representing the two most prevalent chronic non-communicable diseases, i.e., Diabetes and Obesity According to Ayurveda, both conditions are referred to as Prameha and Sthoulya, respectively. Both the conditions are Santarpanottha Vyadhi (diseases arising from excessive and improper nutrition), having the common vitiation of Kapha Dosha, Meda Dhatu and Ama and similar lines of treatment. Haritaki or Abhaya (Terminalia chebula) is a herb that has the potential to manage both diabetes and obesity. The present study focuses on the efficacy of Abhaya Ghana Vati as a single drug regime coupled with Pathya Aahara Vihara (diet and lifestyle regime) in the management of diabesity. Methods: Abhaya Ghana Vati along with Pathya Aahara Vihara (diet and lifestyle regime), was administered in 41 patients for three months, including follow-up. The patients were assessed for the effect of the intervention on the subjective and objective criteria. Results: The intervention showed significant improvement in most of the parameters of outcome measures like BMI (27% improvement, p<0.001), Waist Hip Ratio (p<0.002), Abdominal Girth Circumference (p<0.001), Chest Girth circumference (p<0.001), Waist circumference (p<0.001). The Fasting Blood Sugar (FBS) levels declined significantly from the mean (187.4 to 168.9, p<0.048), and PPBS reduced from the mean (260 to 230.4, p<0.011), which was statistically significant. However, HbA1c declined very marginally from the mean of 8.32 to 8.23 (p<0.71). Effect of treatment on subjective parameters like Apatarpana Lakshana, Dhatusamya Lakshana and Quality of Life parameters showed significant change. Conclusions: Administration of Abhaya Ghana Vati and Pathya Aahara Vihara are beneficial in patients of diabesity.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2023-11-02

How to Cite

Joglekar, A. A., Vyas, M., Bhojani, M. K., & Kumar, A. (2023). Effect of <i>Abhaya Ghana Vati</i> along with <i>Pathya Aaahara Vihara</i> (Diet and Lifestyle Regime) on Patients of Diabesity – A Single Arm Clinical Trial. Journal of Natural Remedies, 23(4), 1425–1435. https://doi.org/10.18311/jnr/2023/32931

Issue

Volume 23 Issue 4 October 2023

Section

Research Articles

Categories

License

Copyright (c) 2023 Aishwarya Ashish Joglekar, Mahesh Vyas, Meera K. Bhojani, Anil Kumar (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC
Received 2023-02-07
Accepted 2023-11-02
Published 2023-11-02

 

References

Chadt A, Scherneck S, Joost H-G, Al-Hasani H. Molecular links between obesity and diabetes: “Diabesity” [Internet]. 2000. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK279051/

Wells JCK. The diabesity epidemic in the light of evolution: Insights from the capacity load model. Diabetologia. 2019; 62(10):1740-50. https://doi.org/10.1007/s00125-019-4944-8 DOI: https://doi.org/10.1007/s00125-019-4944-8

The Institute for Health Metrics and Evaluation. Global diabetes cases to soar from 529 million to 1.3 billion by 2050 [Internet]. 2023. [cited 2023 Aug 26]. Available from: https://www.healthdata.org/newsevents/newsroom/newsreleases/global-diabetes-cases-soar-529-million-13billion-2050

Sharma S. Ashtanga Samgraha of Vagbhata, Sootra Sthana; Dwividhopakramaniya Adhyaya: Chapter 24, Verse 10-16. Varanasi: Chowkhambha Sanskrit Series. 2006: 37-8.

Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP. Indian herbs and herbal drugs used for the treatment of diabetes. Journal of Clinical Biochemistry and Nutrition. 2007; 40(3):163-73. https://doi.org/10.3164/jcbn.40.163 DOI: https://doi.org/10.3164/jcbn.40.163

Murali YK, Anand P, Tandon V, Singh R, Chandra R, Murthy PS. Long-term effects of Terminalia Chebula Retz. on hyperglycaemia and associated hyperlipidaemia, tissue glycogen content and in vitro release of insulin in streptozotocin induced diabetic rats. Experimental and Clinical Endocrinology and Diabetes. 2007; 115(10):641-6. https://doi.org/10.1055/s-2007-982500 DOI: https://doi.org/10.1055/s-2007-982500

WHO. Diagnosis and Management of Type 2 Diabetes (HEARTS-D). Geneva: World Health Organization. (WHO/ UCN/NCD/20.1). Licence: CC BY-NC-SA 3.0 IGO; 2020.

Merriam-Webster. Diabesity [Internet]. n.d. [cited 2023 Aug 26]. Available from: https://www.merriamwebster.com/medical/diabesity

Obesity WPRO [Internet]. [cited 2023 Aug 26].

Available from: https://www.who.int/westernpacific/health-topics/ obesity

Schellong K, Neumann U, Rancourt RC, Plagemann A. Increase of long-term ‘diabesity’ risk, hyperphagia, and altered hypothalamic neuropeptide expression in neonatally over nourished ‘Small-For-Gestational-Age’ (SGA) Rats. PLoS One. 2013; 8(11). https://doi.org/10.1371/journal.pone.0078799 DOI: https://doi.org/10.1371/journal.pone.0078799

Non-communicable diseases: Risk factors [Internet]. [cited 2023]. Available from: https://www.who.int/data/gho/data/ themes/topics/topic-details/GHO/ncd-risk-factors

Farag YMK, Gaballa MR. Diabesity: An overview of a rising epidemic. Nephrology Dialysis Transplantation. 2011; 26(1):28-35. https://doi.org/10.1093/ndt/gfq576 DOI: https://doi.org/10.1093/ndt/gfq576

Scherer PE, Hill JA. Obesity, diabetes, and cardiovascular diseases: A compendium. Circulation Research. 2016; 118(11):1703-5. https://doi.org/10.1161/CIRCRESAHA.116.308999 DOI: https://doi.org/10.1161/CIRCRESAHA.116.308999

Bulbul MRH, Chowdhury MNU, Naima TA, Sami SA, Imtiaj MS, Huda N, et al. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon. 2022; 8(8):e10220. https://doi.org/10.1016/j.heliyon.2022.e10220 DOI: https://doi.org/10.1016/j.heliyon.2022.e10220

Mobley CC. Lifestyle interventions for “diabesity”: the state of the science. Compendium of Continuing Education in Dentistry. 2004; 25(3):207-8, 211-2, 214-8.

Acharya YT. Agnivesha, Charaka Samhita with Ayurveda Dipika commentary by Chakrapani Datta, Chikitsasthana, Pramehachikitsitam Adhyaya, 6/15, reprinted, Varanasi: Chaukhambha Sanskrit Sansthan. 2020; p. 446.

Vaidya B. Nighantu Adarsha, Haritakyadi Varga, Chapter 48, Vol. 1, Varanasi: Chaukhambha Bharati Academy. 2018; p. 550-551.